For Institutional Investors in the US

Global Life Sciences

By understanding the science and business of health care, our experienced team seeks to invest in companies addressing unmet medical needs or improving efficiencies.

View Related Mutual Fund

Overview

ABOUT THIS STRATEGY

We believe in the power of deep, fundamental research to identify life science companies trading at a significant discount to intrinsic value. We feel the quality of our team, the depth of our research and our disciplined long-term approach set us apart in pursuing superior risk-adjusted results for our clients.

INVESTMENT APPROACH

Health Care Expertise: Our domain experts have 95+ years of combined experience investing in the complex and dynamic health care sector. Our team of specialists, which include multiple Ph.D.’s, seek to understand both the science and the business of prospective investments.

Balanced Approach: We diversify the portfolio across market capitalizations, geographies and the primary sub-sectors of health care, including investments in biotechnology, health care services, medical devices and pharmaceuticals.

Integrated Risk Management Process: Security-level “Value at Risk” framework focuses attention on downside risks by limiting the position size of higher-risk stocks.

Featured Insight

Equity Perspectives

Quarterly insight from our equity teams to help clients navigate the markets and opportunities ahead.

Read More

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Andy Acker, CFA

Global Life Sciences | Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, PhD, CFA

Daniel Lyons, PhD, CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

RETURNS (%) (As of 12/31/2022)
Composite Gross Composite Net MSCI World Health Care Index (Gross)
 
3M YTD 1YR 3YR 5YR 10YR Since Inception
(01/01/1999)
Composite Gross 14.29 -1.84 -1.84 9.71 12.30 16.30 12.25
Composite Net 14.07 -2.62 -2.62 8.84 11.45 15.49 11.19
MSCI World Health Care Index (Gross) 13.24 -4.97 -4.97 9.28 10.75 12.59 7.36
Past performance cannot guarantee future results. Investing involves risk, including the possible loss of principal and fluctuation of value. Returns greater than one year are annualized. Returns are expressed in U.S. dollars unless otherwise stated. Composite returns are net of transaction costs and gross of non-reclaimable withholding taxes (if any and unless otherwise noted), and reflect the reinvestment of dividends and other earnings.
The gross performance results presented do not reflect the deduction of investment advisory fees. Returns will be reduced by such advisory fees and other expenses as described in the individual contract and, where applicable, Form ADV Part 2A.
Net performance results do not reflect the deduction of investment advisory fees actually charged to the accounts in the composite but do reflect the deduction of model investment advisory fees based on the maximum fee rate in effect for the respective time period, adjusted for performance-based fees where applicable. Actual advisory fees may vary among clients invested in the strategy and may be higher or lower than model fees. Returns for each client will be reduced by such fees and expenses as described in the individual contract and, where applicable, in Form ADV Part 2A.
Prior to 2008, net returns shown are net of all fees and expenses.
For a complete list of holdings as of the most recently available disclosure period, contact us.
RETURNS (%) (As of 02/28/2023)
Composite Gross Composite Net MSCI World Health Care Index (Gross)
 
3M YTD 1YR 3YR 5YR 10YR Since Inception
(01/01/1999)
Composite Gross -4.43 -3.72 3.18 11.49 10.64 14.80 11.98
Composite Net -4.63 -3.85 2.36 10.61 9.80 13.99 10.93
MSCI World Health Care Index (Gross) -5.75 -4.65 -1.77 10.63 9.50 11.16 7.10
Past performance cannot guarantee future results. Investing involves risk, including the possible loss of principal and fluctuation of value. Returns greater than one year are annualized. Returns are expressed in U.S. dollars unless otherwise stated. Composite returns are net of transaction costs and gross of non-reclaimable withholding taxes (if any and unless otherwise noted), and reflect the reinvestment of dividends and other earnings.
The gross performance results presented do not reflect the deduction of investment advisory fees. Returns will be reduced by such advisory fees and other expenses as described in the individual contract and, where applicable, Form ADV Part 2A.
Net performance results do not reflect the deduction of investment advisory fees actually charged to the accounts in the composite but do reflect the deduction of model investment advisory fees based on the maximum fee rate in effect for the respective time period, adjusted for performance-based fees where applicable. Actual advisory fees may vary among clients invested in the strategy and may be higher or lower than model fees. Returns for each client will be reduced by such fees and expenses as described in the individual contract and, where applicable, in Form ADV Part 2A.
Prior to 2008, net returns shown are net of all fees and expenses.
For a complete list of holdings as of the most recently available disclosure period, contact us.

Documents

Related Insights

Our intellectual capital is readily available and central to our Knowledge Shared approach"
Related Insights
Global Perspectives: Why biotech could be embarking on a new decade of growth
Mar 20, 2023

Global Perspectives: Why biotech could be embarking on a new decade of growth

A wave of innovative therapies is beginning to hit the market, transforming the prospects of the biotech firms behind the science.

24 min read

Two sides of healthcare, one strong investment case
Mar 7, 2023
Timely & Topical

Two sides of healthcare, one strong investment case

The healthcare sector has been resilient through market drawdowns but also benefits from significant long-term growth drivers.

7 min read

Biotech rides a wave of positive data
Feb 2, 2023
Timely & Topical

Biotech rides a wave of positive data

Positive clinical trial data in 2022 could lead to record drug launches over the coming year.

3 min read